Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna, Merck's skin cancer vaccine shows sustained benefit after five years
06:25am, Tuesday, 20'th Jan 2026
Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in combination with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial.
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
06:00am, Tuesday, 20'th Jan 2026
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510;
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Friday, 16'th Jan 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?
09:57am, Thursday, 15'th Jan 2026
MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
06:51pm, Wednesday, 14'th Jan 2026
Moderna (MRNA) closed the most recent trading day at $40.6, moving +2.52% from the previous trading session.
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday?
01:04pm, Tuesday, 13'th Jan 2026
Wall Street traded timidly on Tuesday despite another benign inflation report that reinforced expectations for Federal Reserve rate cuts later this year, as a weaker-than-expected start to the earning
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story
08:15am, Tuesday, 13'th Jan 2026
Moderna is undergoing a strategic shift, prioritizing infectious disease, oncology, and rare diseases to achieve cash break-even by 2028. 2026 is pivotal, with multiple oncology catalysts—especially
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10:26pm, Monday, 12'th Jan 2026
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Moderna expects 2025 revenue of $1.9B, above guidance
12:49pm, Monday, 12'th Jan 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously communicated guidance of $1.6 to $2 billion. Th
Moderna Stock Rises. Revenue in 2025 Will Be Higher Than Midpoint of Guidance.
08:51am, Monday, 12'th Jan 2026
Moderna also reiterates its expectations for revenue growth of up to 10% in 2026.
Moderna expects 2025 revenue of $1.9B, above guidance
07:45am, Monday, 12'th Jan 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously...
Moderna expects $1.9 billion in sales, trims costs forecast for 2025
07:12am, Monday, 12'th Jan 2026
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its previously projected $1.6 billion to $2 billion forecast but well below
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 12'th Jan 2026
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call Improves 2025 expected GAAP operating expenses by $200 million since 3Q25
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
06:51pm, Thursday, 08'th Jan 2026
In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 07'th Jan 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
